<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118113</url>
  </required_header>
  <id_info>
    <org_study_id>SI101-HV1</org_study_id>
    <nct_id>NCT05118113</nct_id>
  </id_info>
  <brief_title>Development of a Cell Culture Process for the Production of Human T-lymphocyte Precursors</brief_title>
  <acronym>SMART101-HV1</acronym>
  <official_title>Development of a Cell Culture Process for the Production of Human T-lymphocyte Precursors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smart Immune SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smart Immune SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to finalise the development of a process for the production of&#xD;
      T-cell progenitor cells.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Production of cell therapy products fulfilling the required specifications</measure>
    <time_frame>7 days</time_frame>
    <description>Production of cell therapy products fulfilling the required specifications after 7 days of CD34+ cell culture</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Healthy donors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collection of mobilized hematopoietic stem cells (apheresis products) from healthy volunteers</intervention_name>
    <description>Mobilisation of hematopoietic stem cells by injection of filgrastim (authorized auxiliary medicinal product) for 4 consecutive days and leukapheresis on Day 5</description>
    <arm_group_label>Healthy donors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy donors, men aged 18 to 40 years.&#xD;
&#xD;
          -  Body weight ≥ 65 kg with a body mass index (BMI) calculated by weight in kg/(height in&#xD;
             m)² of 20 to 30 kg/m² at screening.&#xD;
&#xD;
          -  Informed consent form signed and dated prior to any study-specific screening&#xD;
             procedure.&#xD;
&#xD;
          -  Health status judged by the investigator to be compatible with participation in the&#xD;
             study based on medical history, results of physical examination, results of biological&#xD;
             laboratory tests (cell blood count including RBC, hematocrit, hemoglobin,&#xD;
             reticulocytes, WBC, platelet, PT, aPTT, CRP, fasting blood glucose, ionogram (Na+, K+,&#xD;
             Cl-, HCO3-), creatinine, creatinine clearance by Cockcroft, albumin, total protein,&#xD;
             total bilirubin, AST, ALT, ALP, GGT), vital signs measurements and 12-lead ECG. All&#xD;
             results should be normal or, if out of range, clinically insignificant in the&#xD;
             judgement of the investigator.&#xD;
&#xD;
          -  Venous capital compatible with leukapheresis&#xD;
&#xD;
          -  Have a high probability of complying with and completing the study.&#xD;
&#xD;
          -  Be affiliated with a Social Security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any cardiovascular (e.g. heart failure), hepatic, renal, respiratory (e.g. asthma),&#xD;
             gastrointestinal, endocrine (e.g. diabetes, dyslipidemia), immunological,&#xD;
             dermatological, haematological (including hemoglobinopathy), neurological, psychiatric&#xD;
             disorder or any history of allergy to a drug.&#xD;
&#xD;
          -  State of acute illness (e.g., vomiting, fever, diarrhea) within 7 days prior to the&#xD;
             first day of the study.&#xD;
&#xD;
          -  History of drug abuse in the year preceding the first day of the study.&#xD;
&#xD;
          -  History of alcoholism in the year prior to day 1 defined as consumption of more than 3&#xD;
             standard drinks/day (30 g/day) or 15 standard drinks/week (150 g/week) or less than&#xD;
             two non-alcoholic days each week, or more than 5 standard drinks (50 g) on a single&#xD;
             occasion.&#xD;
&#xD;
          -  Any contra-indication to filgrastim&#xD;
&#xD;
          -  Positive serological results for human immunodeficiency virus (HIV) antibodies,&#xD;
             hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, syphilis&#xD;
             and/or human T-lymphotropic virus (HTLV).&#xD;
&#xD;
          -  Positive urine drug tests (methadone, barbiturates, benzodiazepines, tricyclic&#xD;
             antidepressants, cocaine, cannabinoids, morphine, amphetamines and methamphetamines,&#xD;
             including 3,4-methylenedioxy-N-methylamphetamine [MDMA]).&#xD;
&#xD;
          -  Laboratory workup including blood count, fasting blood glucose, blood ionogram,&#xD;
             creatinine, AST, ALT, gamma GT, alkaline phosphatase, total bilirubin, CRP, PT, aPTT&#xD;
             incompatible with leukapheresis protocol.&#xD;
&#xD;
          -  Use of any experimental drug within 30 days prior to inclusion.&#xD;
&#xD;
          -  Use of any prescription or over-the-counter medication within 5 times the elimination&#xD;
             half-life prior to inclusion. However, any prescribed medication that may interfere&#xD;
             with the study objectives must be discontinued for at least 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joe-Elie Salem, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIC Paris Est, Hôpital Pitié Salpêtrière, Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marina CAVAZZANA, MD, PhD</last_name>
    <phone>+33 1 88 33 82 59</phone>
    <email>marina.cavazzana@smart-immune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CIC Paris Est, Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>For information on study participation</last_name>
      <phone>+33 1 42 17 85 31</phone>
      <email>secretariat.cic.psl@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Joe-Elie Salem, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2021</study_first_submitted>
  <study_first_submitted_qc>November 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

